|
Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults without Previous Smallpox Vaccination Clinical Trials Resources presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, visits or professional assistance with a real medical. We aren't doctors. Always consult your mD about Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults without Previous Smallpox Vaccination conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults without Previous Smallpox Vaccination Clinical research trials and Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults without Previous Smallpox Vaccination health trials occur in a lot of of places throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new does drugs. The role of the studies / projects is to resolve certain human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector corporations to detect remedies for all varieties of circumstances, such as Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults without Previous Smallpox Vaccination. Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults without Previous Smallpox Vaccination Clinical Trials and other clinical trials allow volunteers to obtain health treatment choices before they are available to the general public. Most times the human subjects recieve professional assistance for free of charge, and every now and again they are paid for their time. Sometimes there is a cost for a Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults without Previous Smallpox Vaccination clinical trial. Human subjects frequently get the finest healthcare available for their Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults without Previous Smallpox Vaccination condition. Risks are a reality, however, and may include extra or frequent physician visits, medical dangers (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "D" Clinical Trials Conditions > Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults without Previous Smallpox Vaccination  Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults without Previous Smallpox Vaccination
Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults without Previous Smallpox Vaccination
For Condition: Smallpox
Status: No longer recruiting
Sponsor(s): Acambis ,
Synopsis: The purpose of this study is to examine the safety and the effectiveness of a new vaccine for the prevention of the disease, smallpox.
Details: In addition to assessment of safety parameters, the objective of this study is to determine the minimum dose of ACAM1000 that is calculated to produce a major cutaneous reaction in at least 90% of a population of healthy adults 18-29 years of age and naïve to smallpox vaccine. Specifically, the objectives of this study are to: 1. Compare the safety and tolerability of three dose levels of ACAM1000 and a standard dose of Dryvax® in healthy adults 18-29 years of age and naïve to smallpox vaccine. Safety and tolerability will be determined by examination of the local cutaneous reaction, adverse events, physical examinations, vital signs, structured interviews, and laboratory analysis. 2. Determine the immunogenicity of three dose levels of ACAM1000 and a standard dose of Dryvax® in healthy adults 18-29 years of age by comparing: (a)the proportion of subjects at each dose level who develop a major cutaneous reaction; (b)the proportion of subjects in each treatment group who develop neutralizing antibodies, including the fold-increase in antibody titer between Baseline and Day 30 sera; and the geometric mean vaccinia neutralizing antibody titer on Day 30. 3. Determine the minimum dose of ACAM1000 that is calculated to produce a major cutaneous reaction in at least 90% of a population of healthy adults 18-29 years of age and naïve to smallpox vaccine.
Eligibility:
Study Type: Interventional, Prevention, Randomized, Double-Blind, Dose Comparison, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/29 Years
Genders: Both
Protocol Entry Criteria: Subjects must meet these inclusion criteria: - in good general health. - not pregnant and using effective birth control If any of the following exclusion criteria are met, the subject is not eligible for the study: - military service prior to 1989. - no previous smallpox vaccination. - no contact with with children 1 year of age or younger - immunodeficiency individuals or close contacts who are immunodeficient - past history or current renal disease - diagnosis or past history of eczema - known allergy or past allergic reactions to latex gloves or to some antibiotics (neomycin, streptomycin, chlortetracycline, and polymyxin B). - known allergy or past allergic to blood products. - known allergy or past allergic reaction to cidofovir or sulfa-containing drugs. - transfusion of blood or treatment with any blood product, including intramuscular or intravenous serum globulin within six months of the Screening Visit. - serology positive for HIV, hepatitis B or hepatitis C. - current diagnosis or history within six months of drug or alcohol abuse disorders, psychiatric illness. - inoculation with any other live vaccine within 30 days of Day 0 or participation in another drug or vaccine trial within 30 days of Day 0.
Total Enrollment: 350
Location and Contact Information:
Radiant Research
Cincinnati, Ohio, 45236
United States
Mayo Vaccine Research Group
Rochester, Minnesota, 55905
United States
Orlando Clinical Research Center
Orlando, Florida, 32806
United States
Additional Information:
Study ID Numbers: H-300-002;
Study Start Date: September 2002
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00053508
Other Smallpox Studies:
1. Vaccinia virus vaccine (APSV) in vaccinia- naive subjects: PILOT
2. Human Immune Response to Smallpox Vaccine
3. Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination
4. Safety, Tolerability, and Immune Response of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Adults
5. A Study of Dryvax Vaccine Against Smallpox in Previously Unvaccinated Adults
Related Studies:
Other Smallpox Clinical Trials
Other Ohio Clinical Trials
Other Cincinnati Clinical Trials
Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults without Previous Smallpox Vaccination
|
|
|
|
|
|
|
|
